Shirin Bruderer
Overview
Explore the profile of Shirin Bruderer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Axelsen L, Poggesi I, Rasschaert F, Perez Ruixo J, Bruderer S
Br J Clin Pharmacol
. 2020 May;
87(1):119-128.
PMID: 32415684
Aims: Selexipag is a prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension. Cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite,...
2.
Grill S, Bruderer S, Sidharta P, Antonova M, Globig S, Carlson J, et al.
Br J Clin Pharmacol
. 2020 May;
86(12):2424-2434.
PMID: 32374030
Aims: To demonstrate the bioequivalence of macitentan/tadalafil fixed-dose combination (FDC) tablets with single-component tablets of macitentan and tadalafil in healthy subjects. Methods: Studies AC-077-101 and AC-077-103 were single-centre, open-label, single-dose,...
3.
Csonka D, Bruderer S, Schultz A, Soergel M, Stepanova R, Sabattini G, et al.
Clin Drug Investig
. 2019 Sep;
39(12):1223-1232.
PMID: 31552642
Background: Macitentan is a clinically approved endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH). Increasing use of combination drug therapy in PAH means that it is important...
4.
Bruderer S, Petersen-Sylla M, Boehler M, Remenova T, Halabi A, Dingemanse J
Br J Clin Pharmacol
. 2017 Jul;
83(12):2778-2788.
PMID: 28715853
Aims: Based on in vitro data, there is evidence to suggest that cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite, ACT-333679. The present...
5.
Boehler M, Bruderer S, Ulc I, Dingemanse J
Eur J Drug Metab Pharmacokinet
. 2017 Jun;
43(1):115-120.
PMID: 28639216
Background And Objectives: Selexipag is an oral, non-prostanoid, selective prostacyclin receptor agonist recently marketed for the treatment of pulmonary arterial hypertension (PAH) in adults. Selexipag may also be an effective...
6.
Juif P, Boehler M, Donazzolo Y, Bruderer S, Dingemanse J
Eur J Clin Pharmacol
. 2017 Jun;
73(9):1121-1128.
PMID: 28639119
Purpose: In vitro data showed that selexipag and its active metabolite (ACT-333679) have an inductive effect on CYP3A4, CYP2B6, and CYP2C9 at concentrations approximately 100-fold higher than the maximum plasma...
7.
Bruderer S, Hurst N, Remenova T, Dingemanse J
Expert Opin Drug Saf
. 2017 May;
16(6):743-751.
PMID: 28494686
Selexipag is the first oral, non-prostanoid, selective prostacyclin receptor (IP receptor) agonist, approved for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients. Areas covered: This article reviews...
8.
Bruderer S, Okubo K, Mukai H, Mant T, Dingemanse J
Clin Ther
. 2016 Apr;
38(5):1228-1236.e1.
PMID: 27063071
Purpose: Selexipag is a new orally available nonprostanoid prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Warfarin is commonly used in patients with pulmonary arterial hypertension. Possible pharmacodynamic...
9.
Baldoni D, Bruderer S, Muhsen N, Dingemanse J
Int J Clin Pharmacol Ther
. 2015 Jul;
53(9):788-98.
PMID: 26152132
Objective: Selexipag is a novel, oral, selective prostacyclin (PGI2) receptor agonist in clinical development for the treatment of pulmonary arterial hypertension. Film-coated tablets with strength between 200 and 1,600 μg...
10.
Kaufmann P, Niglis S, Bruderer S, Segrestaa J, Aanismaa P, Halabi A, et al.
Br J Clin Pharmacol
. 2015 Apr;
80(4):670-7.
PMID: 25851691
Aims: This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on the pharmacokinetics (PK) of selexipag and its active metabolite ACT-333679. Methods: This was an open label,...